ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.